
|Videos|October 14, 2022
Efficacy and Quality of Life Data from 5-Year Follow-Up of CheckMate 214
Author(s)Rana R. McKay, MD
Dr Rana McKay discusses the efficacy and qualify-of-life data from the 5-year follow-up of the CheckMate 214 trial investigating nivolumab plus ipilimumab in frontline advanced renal cell carcinoma treatment.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
The Targeted Pulse: FDA Decisions and Clinical Advancements
2
FDA Accepts NDA for 177Lu-edotreotide in GEP-NETs
3
Long-Term Follow-Up Confirms Benefits of Low-Dose Seminoma Treatment
4
FDA Authorizes EXENT System to Aid Myeloma Diagnosis
5









































